Menopause, Rheumatoid Arthritis
Conditions
Keywords
Magnetics, Pulsed Magnetic Pad, Magnetic Field, Electromagnetic Field, Women, Pulsed Magnetic Field
Brief summary
The purpose of this study is to determine whether a pulsed magnetic field (PMF) pad will improve symptoms of rheumatoid arthritis (RA) in postmenopausal women. Study hypothesis: A pulsed magnetic field pad will effectively reduce the symptoms of RA in postmenopausal women.
Detailed description
RA is a condition characterized by pain, fatigue, sleep disturbances, and mood changes. These symptoms often persist despite the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying antirheumatic drugs (DMARDs). Many women for whom these drugs do not work turn to complementary and alternative therapies, including the use of magnetic devices. Although few studies have investigated the effects of low strength PMF pads in persons with RA, evidence suggests that PMF may help relieve pain, inflammation, and fatigue. This study will determine the effects of a PMF device on RA symptoms in postmenopausal women. This study will last 12 weeks. Participants will be randomly assigned to one of three groups: active PMF pad treatment, sham PMF pad treatment, or standard of care, which may include drug therapy or physical therapy. Participants in the active and sham PMF pad groups will be treated with their assigned pad for approximately 8 minutes, twice a day for the duration of the study. Questionnaires and self-report scales will be used to assess pain, fatigue, sleep quality, mood, and inflammation episodes. Blood and urine collection will occur to assess levels of stress hormones and certain proteins.
Interventions
DEVICEPulsed magnetic field pad
Sponsors
National Center for Complementary and Integrative Health (NCCIH)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
FEMALE
Age
35 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of RA * Postmenopausal, defined by no menstrual period in at least 2 years prior to study entry or a hysterectomy * Average pain of 2 or greater on a 0 to 10 pain scale * Sleep difficulty * Stable medication use related to RA for at least 4 weeks prior to study entry
Exclusion criteria
* Diagnoses of lupus, sleep apnea, or restless leg syndrome * High-dose prednisone (more than 10 mg/day) or equivalent * Pacemakers or other implanted devices * Epilepsy * Currently undergoing treatment for cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain | — |
Secondary
| Measure | Time frame |
|---|---|
| sleep disturbances | — |
| depression | — |
| perceived stress | — |
| stress hormones (norepinephrine and epinephrine) | — |
| cortisol | — |
| Fatigue | — |
| erythrocyte sedimentation rate (ESR) | — |
| C-reactive protein (CRP) | — |
| functional status | — |
| feasibility of study | — |
| pro-inflammatory cytokines (IL-1, IL-6) | — |
Countries
United States
Outcome results
None listed